Clinical trial

Effect of Ensifentrine Treatment on CAT Score

NCT06460493

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2024-06-11

PhasePHASE3

Study timeline

Study start (actual)2024-06-11Date precision: day

Registry last updated2025-04-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

COPDunresolved

Interventions

Ensifentrine 3 mg twice dailyDRUG

Sponsors & collaborators

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAlead sponsor

Midwest Chest Consultantscollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06460493 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.